ALT - Altimmune, Inc.
| Previous Close | 2.3300 |
| Open | 2.4100 |
| Bid | 2.3800 x 1000 |
| Ask | 2.3900 x 1800 |
| Day's Range | 2.3100 - 2.5400 |
| 52 Week Range | 1.7000 - 36.2500 |
| Volume | 1,115,793 |
| Avg. Volume | 319,969 |
| Market Cap | 36.504M |
| Beta (3Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.9840 |
| Earnings Date | Aug 8, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-01-20 |
| 1y Target Est | 10.00 |
- GlobeNewswire•4 days ago
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). The number of shares to be issued was determined based on the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty consecutive trading days prior to and including July 8, 2019, the date the definitive agreement was signed. Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies.
- American City Business Journals•7 days ago
Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.
- American City Business Journals•10 days ago
Altimmune to acquire California company for up to $93M
The deal puts Spitfire’s flagship product candidate — a treatment for nonalcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.
- American City Business Journals•10 days ago
Germantown stem cell therapy company proposes $7M offering amid delisting threat
The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.
- Benzinga•10 days ago
Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio
Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...
- MarketWatch•10 days ago
Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma
Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH. Altimmune will make an upfront payment of $5 million to Spitfire shareholders, who will also be eligible to receive an additional $8 million in regulatory and clinical milestones and up to $80 million in sales-based milestones. The deal is expected to close in July. Spitfire's NASH product candidate SP-1373 will be renamed ALT-801. "Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease," said Altimmune Chief Executive Vipin Garg. Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.
- GlobeNewswire•10 days ago
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
Company to conduct conference call on Tuesday, July 9, 2019 at 8:30 a.m. GAITHERSBURG, Md., July 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).
- GlobeNewswire•last month
Altimmune Appoints Will Brown as Chief Financial Officer
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to be a valuable member of our senior leadership team since he stepped into the CFO role over a year ago,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer.
- GlobeNewswire•last month
Altimmune Announces Successful Pre-IND Meeting with FDA
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial design and manufacturing plans for HepTcell. The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of Phase 2 trials. Altimmune intends to conduct a Phase 2 study in the United States and the pre-IND meeting was held to obtain feedback from the FDA on our intended development path.
- GlobeNewswire•last month
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual property protection with the additional patents covering our development candidates, HepTcell and ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. For HepTcell, the Company has been granted U.S. Patent No. 10,300,132 entitled “Vaccines Against Hepatitis B Virus.” The patent, which expires in 2035 accounting for 515 days of patent term adjustment, provides important additional IP protection for the HepTcell clinical development program, an immunotherapeutic being developed for patients chronically infected with the hepatitis B virus (“HBV”).
- GlobeNewswire•2 months ago
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
GAITHERSBURG, Md., May 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended.
- GlobeNewswire•2 months ago
Altimmune to Announce First Quarter 2019 Financial Results on May 15
GAITHERSBURG, Md., May 08, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.
- GlobeNewswire•3 months ago
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel at 12:55pm Eastern Time. Dr. Sybil Tasker, Chief Medical Officer of Altimmune, will present data from the Company’s Phase 2 study and the recently completed Phase 2 extension study for NasoVAX.
- ACCESSWIRE•4 months ago
Altimmune, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30:00 AM Eastern ...
- GlobeNewswire•4 months ago
Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
GAITHERSBURG, Md., April 01, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December.
- GlobeNewswire•4 months ago
Altimmune to Announce Year End 2018 Financial Results on April 2
GAITHERSBURG, Md., March 21, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.
- InvestorPlace•4 months ago
Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.
- GlobeNewswire•4 months ago
Altimmune Announces Positive Results from NasoVAX Extension Study
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination.
- GlobeNewswire•4 months ago
Altimmune to Participate at 31st Annual ROTH Conference
GAITHERSBURG, Md., March 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief.
- GlobeNewswire•4 months ago
Altimmune Announces Closing of $14 Million Registered Direct Offering
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million. On March 8, 2019, the Company disclosed approximately $34.4 million in cash, cash equivalents and restricted cash as of December 31, 2018. Altimmune intends to use the cash on hand together with the net proceeds of approximately $12.7 million from this offering for the continued advancement and development activities for its product pipeline, strategic growth opportunities (including potential acquisitions and/or licensing transactions), and general working capital purposes.
- GlobeNewswire•4 months ago
Altimmune Announces $14 million Registered Direct Offering
Each common unit is being sold at a public offering price of $3.21 and consists of one share of common stock and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21. Each pre-funded unit is being sold at a public offering price of $3.20 and consists of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21.
- GlobeNewswire•6 months ago
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12, 2019 at The International Liver Congress sponsored by The European Association for the Study of the Liver (EASL) being held in Vienna, Austria April 10-14, 2019. As previously announced, this study met its primary endpoint of safety and showed that HepTcell treatment was associated with increased HBV-specific cellular immune responses.
- ACCESSWIRE•7 months ago
Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
- GlobeNewswire•7 months ago
Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. As previously announced in September 2018, a monovalent version of NasoVAX, Altimmune's intranasally administered influenza vaccine candidate, elicited statistically significant mucosal antibody responses not seen with the commercially available injectable vaccine Fluzone®, and a nearly 6-fold higher median cellular immune response compared to Fluzone. In addition, the NasoVAX hemagglutination inhibition (HAI) antibody response was stable over the six-month follow-up period, while antibody titers elicited by Fluzone fell over 50% over the same period. The Company is now conducting an extension study for previous Phase 2a study participants to measure further durability of HAI responses one year after vaccination and will be evaluating other clinical measures of NasoVAX immunogenicity.
